Literature DB >> 12672843

Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis.

Jaimo Ahn1, Lourdes Serrano de la Pena, Eileen M Shore, Frederick S Kaplan.   

Abstract

BACKGROUND: Fibrodysplasia ossificans progressiva is a rare genetic disorder characterized by congenital malformations of the great toes and by progressive heterotopic bone formation. Bone morphogenetic protein-4 (BMP-4) messenger ribonucleic acid (mRNA) and protein are uniquely overexpressed in lymphocytes and lesional cells from patients who have fibrodysplasia ossificans progressiva. However, the BMP-4 gene is not mutated in fibrodysplasia ossificans progressiva. The activities of BMPs are specified in part by the formation of morphogen gradients that are further regulated by an array of secreted antagonists. Recent studies have indicated that BMP-4 upregulates the expression of the BMP antagonists noggin, gremlin, and follistatin, thereby establishing an autoregulatory feedback loop. Therefore, a defect in the feedback pathway between BMP-4 and one or more of its extracellular antagonists could contribute to the elevated BMP-4 activity characteristic of fibrodysplasia ossificans progressiva.
METHODS: Basal and BMP-4-induced expression of noggin, gremlin, follistatin, and chordin mRNA were investigated in control and fibrodysplasia ossificans progressiva lymphoblastoid cell lines with use of reverse transcriptase-polymerase chain reaction and Northern analysis.
RESULTS: In the absence of exogenous BMP-4 stimulation (basal state), steady-state levels of all of the BMP antagonists that were investigated were similar in fibrodysplasia ossificans progressiva and control cell lines. Upon stimulation with recombinant human BMP-4, control lymphoblastoid cell lines exhibited a marked increase in expression of noggin and gremlin mRNA. Fibrodysplasia ossificans progressiva cells, however, showed a dramatically attenuated response to BMP-4 stimulation compared with that of controls.
CONCLUSIONS: These data indicate a paresis of a BMP-antagonist response, suggesting the loss of a negative feedback mechanism by which cells normally regulate the magnitude and boundaries of ambient morphogenetic signals. This paresis may account in part for the increased BMP-4 activity in fibrodysplasia ossificans progressiva.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672843     DOI: 10.2106/00004623-200304000-00013

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  31 in total

1.  Myositis ossificans within the intercondylar notch treated arthroscopically.

Authors:  Allen H Leung; Leon D Rybak; Donald J Rose; Panna Desai
Journal:  Skeletal Radiol       Date:  2010-06-08       Impact factor: 2.199

2.  Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Petra Seemann; Julia Haupt; Meiqi Xu; Vitali Y Lounev; Mary Mullins; Eileen M Shore
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 3.  Heterotopic ossification: a review.

Authors:  E F McCarthy; M Sundaram
Journal:  Skeletal Radiol       Date:  2005-08-25       Impact factor: 2.199

4.  Hypoxic adipocytes pattern early heterotopic bone formation.

Authors:  Elizabeth Olmsted-Davis; Francis H Gannon; Mustafa Ozen; Michael M Ittmann; Zbigniew Gugala; John A Hipp; Kevin M Moran; Christine M Fouletier-Dilling; Shannon Schumara-Martin; Ronald W Lindsey; Michael H Heggeness; Malcolm K Brenner; Alan R Davis
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 5.  True trilineage haematopoiesis in excised heterotopic ossification from a laparotomy scar: report of a case and literature review.

Authors:  Theodoros Christofi; Dimitri A Raptis; Andreas Kallis; Faisal Ambasakoor
Journal:  Ann R Coll Surg Engl       Date:  2008-07       Impact factor: 1.891

6.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

7.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

8.  Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro.

Authors:  Wei Zhu; Jaehon Kim; Christina Cheng; Bernard A Rawlins; Oheneba Boachie-Adjei; Ronald G Crystal; Chisa Hidaka
Journal:  Bone       Date:  2006-02-20       Impact factor: 4.398

9.  Biological activity of a genetically modified BMP-2 variant with inhibitory activity.

Authors:  Uwe Klammert; Joachim Nickel; Kristian Würzler; Christoph Klingelhöffer; Walter Sebald; Alexander C Kübler; Tobias Reuther
Journal:  Head Face Med       Date:  2009-02-02       Impact factor: 2.151

10.  Prophylaxis of heterotopic ossification - an updated review.

Authors:  Evan O Baird; Qian K Kang
Journal:  J Orthop Surg Res       Date:  2009-04-20       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.